Key Highlights

  • Claritev Corporation (NYSE:CTEV) filed a Form 8-K under Regulation FD addressing a report that the US Department of Justice had opened a criminal antitrust investigation into it.
  • The most recent reviewed figures cover the three months, reported on 7 May.
  • The turnaround is measurable rather than promised. After several years of shrinking revenue, Claritev has posted two consecutive quarters of roughly 6 per cent growth.
  • Gross debt of US$4.62bn against US$21.3m of cash is roughly 7.5 times the midpoint of guided 2026 adjusted EBITDA.

Why the market is paying attention

Claritev Corporation (NYSE:CTEV) filed a Form 8-K under Regulation FD addressing a report that the US Department of Justice had opened a criminal antitrust investigation into it. The filing confirmed Claritev received a confidential grand jury subpoena from the DOJ's Antitrust Division in August 2024, said it is cooperating fully, and stated it has not been told it is a target.

The timing is awkward, because operationally the business has turned. Revenue grew 3.7 per cent in 2025 to US$965.4m, then 6.2 per cent year on year in the December quarter and 5.8 per cent in the March 2026 quarter.

A legal headline still moves the shares more than a guidance beat, because of the capital structure. Claritev had 17,047,789 Class A shares outstanding, about US$402m of equity at the 30 July close of US$23.58, beneath US$4.62bn of gross long-term debt.

What the company does

Claritev was called MultiPlan Corporation until February 2025 and listed via the Churchill Capital Corp III blank-cheque vehicle in 2020. Per-share figures here are adjusted for the 1-for-40 reverse split effective recently.

The business sits between American health insurers and medical providers, repricing out-of-network claims, determining what a payer should pay when a patient is treated outside the insurer's contracted network. It applies data, analytics and its own negotiated networks, and is paid fees largely linked to the savings it identifies.

In the March quarter, Claims Intelligence Solutions, the analytics-led pricing engine, contributed US$166.3m against US$153.4m a year earlier; Network Solutions US$47.5m against US$46.9m; and Payment and Revenue Integrity Solutions a flat US$30.9m. Scale is genuine: the 2025 annual report cites US$25.0bn of identified savings on US$179.8bn of claim charges.

Latest financial and operating performance

The most recent reviewed figures cover the three months, reported on 7 May. Revenue was US$244.7m, up 5.8 per cent. Adjusted EBITDA, the company's preferred measure, excluding interest, tax, depreciation, amortisation and transformation costs, was US$146.9m, up 3.4 per cent, a 60.0 per cent margin against 61.4 per cent.

Statutory operating income was just US$6.6m, down from US$9.7m, as heavy amortisation of acquisition intangibles and capitalised software runs through the income statement. Interest expense of US$99.5m then drove a net loss of US$73.6m, or US$4.41 per share. Across 2025, revenue of US$965.4m produced adjusted EBITDA of US$602.6m, a net loss of US$284.3m and negative free cash flow of US$12.3m.

Liquidity is tight. Unrestricted cash was US$21.3m, with revolver drawings up to US$125m from US$20m at the year end. The quarter consumed US$45.8m of operating cash and US$46.8m of capital expenditure, a US$92.5m free cash outflow, and shareholders' deficit stood at US$241.1m. Guidance for 2026 is revenue of US$985m to US$1.0bn and adjusted EBITDA of US$605m to US$615m.

The catalyst that matters: criminal exposure on top of a civil case

Claritev already faced substantial civil action. Federal class actions alleging it conspired with commercial payers to suppress out-of-network reimbursements are centralised as multidistrict litigation in the Northern District of Illinois before Judge Matthew F. Kennelly. Motions to dismiss the consolidated complaints were granted in part and denied in part, and discovery continues. The company says the suits are without merit; no loss accrual is disclosed.

A criminal inquiry is different in kind. It carries possible corporate fines and, more importantly, scrutiny aimed at the mechanics of the repricing model rather than any single contract. Nothing has been charged, but the disclosure widens the range of outcomes a refinancing counterparty must price.

That matters because of the maturity profile. A refinancing completed exchanged existing notes into a tiered first-lien structure whose maturities run from December 2029 to December 2031, so there is no near-term wall. Yet the 10-Q values that debt at US$3,643.3m against US$4,624.7m of principal, about 79 cents in the dollar.

The bull case

The turnaround is measurable rather than promised. After several years of shrinking revenue, Claritev has posted two consecutive quarters of roughly 6 per cent growth. Chairman, chief executive and president Travis Dalton said the company 'kicked off 2026 the same way we closed 2025, outperforming on top and bottom lines'.

The economics are unusual. A 60 per cent adjusted EBITDA margin on what is essentially a data and network asset means incremental revenue converts to profit at a high rate; guidance implies about US$610m of adjusted EBITDA on roughly US$1bn of revenue.

The bear case and the risks

Leverage and interest burden. Gross debt of US$4.62bn against US$21.3m of cash is roughly 7.5 times the midpoint of guided 2026 adjusted EBITDA. The March quarter's US$99.5m of interest annualises near US$400m, about two-thirds of that guidance. Swaps covering US$800m of notional at 4.59 per cent expire.

Legal and regulatory overhang. The DOJ subpoena and the provider antitrust MDL are live and unquantified. No disclosed accrual means no estimable liability has been recorded, not that exposure is nil.

Client concentration. One client was 29.2 per cent of 2025 revenue and a second 10.4 per cent. Losing or repricing either would swamp the growth restored so far.

Business-model exposure. Fees are earned on out-of-network claim savings, and the No Surprises Act and wider use of independent dispute resolution structurally shrink that pool.

What investors should watch next

Second-quarter results, for which an 8:00am EDT call is confirmed. The tests are whether growth holds near 6 per cent, whether the margin stabilises, and whether guidance moves again.

Cash, revolver drawings and free cash flow. Borrowings rose from US$20m to US$125m in the March quarter; watch for movement toward the 40 per cent covenant test, and whether the June quarter reverses the US$92.5m outflow.

Legal milestones, including any DOJ development and progress in the Illinois MDL, particularly class certification.

The debt price, marked near 79 cents, which gauges how creditors price the risks equity holders carry.

Investor takeaway

Claritev presents a rare split between operations and capital structure. The business has stopped shrinking, is growing at roughly 6 per cent, and converts revenue to adjusted EBITDA at a 60 per cent margin. Against that, gross debt of US$4.62bn dwarfs a roughly US$402m equity value, interest consumes about two-thirds of guided adjusted EBITDA, and the company is defending an antitrust MDL while cooperating with a DOJ grand jury subpoena.

The January 2025 refinancing removed near-term maturity risk, which is why the equity still trades. But with the debt marked near 79 cents in the dollar, the market is not yet convinced enterprise value covers the borrowings. This is a balance-sheet and litigation story wearing the clothes of an operational recovery.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.